JNJ-90301900

JNJ-90301900 is a radioenhancer nanoparticle developed by Johnson & Johnson Enterprise Innovation. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. The sponsor states: A suspension of inert, crystalline hafnium oxide nanoparticles designed to generate oxygen free radicals that destroy cancer cells once activated by ionising radiation. ClinicalTrials.gov describes the intervention as: Suspension of inert, crystalline hafnium oxide particles, designed to generate oxygen free radicals to destroy cancer cells after activation by ionizing radiation. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT04892173 (JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC), in head and neck squamous cell carcinoma. The largest, NCT04892173, plans to enrol 500 participants with primary completion expected 2028-06-30. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.